Cost-effectiveness of quadrivalent vaccine against human papilloma virus in Argentina based on a dynamic transmission model

Salud Pública de México. 2015;57(6):504-513 DOI 10.21149/spm.v57i6.7639

 

Journal Homepage

Journal Title: Salud Pública de México

ISSN: 0036-3634 (Print)

Publisher: Instituto Nacional de Salud Pública

Society/Institution: Instituto Nacional de Salud Pública

LCC Subject Category: Medicine: Public aspects of medicine

Country of publisher: Mexico

Language of fulltext: Spanish, English

Full-text formats available: PDF, HTML

 

AUTHORS


Andrés Pichon-Riviere (Instituto de Efectividad Clínica y Sanitaria (IECS). Buenos Aires, Argentina.)

Andrea Alcaraz (Instituto de Efectividad Clínica y Sanitaria (IECS). Buenos Aires, Argentina.)

Joaquín Caporale (Instituto de Efectividad Clínica y Sanitaria (IECS). Buenos Aires, Argentina.)

Ariel Bardach (Instituto de Efectividad Clínica y Sanitaria (IECS). Buenos Aires, Argentina.)

Lucila Rey-Ares (Instituto de Efectividad Clínica y Sanitaria (IECS). Buenos Aires, Argentina.)

Karen Klein (Instituto de Efectividad Clínica y Sanitaria (IECS). Buenos Aires, Argentina.)

María Calderón (Instituto de Efectividad Clínica y Sanitaria (IECS). Buenos Aires, Argentina.)

Federico Augustovski (Instituto de Efectividad Clínica y Sanitaria (IECS). Buenos Aires, Argentina.)

Silvio Tatti Tatti (Hospital de Clínicas. Buenos Aires, Argentina.)

EDITORIAL INFORMATION

Double blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 34 weeks

 

Abstract | Full Text

Objective. To assess the cost-effectiveness of the qua- drivalent vaccine against human papillomavirus (HPV) in Argentina from the health system perspective. Materials and methods. A dynamic transmission model was used to estimate the impact of the vaccine on the incidence of cervical cancer, warts, and other HPV related diseases; in quality adjusted life years (QALYs); and in healthcare costs. Results. Vaccination could reduce the risk of cervical cancer by 60% and by 67% the risk of genital warts. Compared to a non-vaccine scenario, the immunization strategy showed an incremental benefit of 0.00234 QALY per person at an incremental cost of US$2.36, resulting in an incremental cost-effectiveness ratio of US$1007.55 per QALY gained. Sensitivity analysis proved the robustness of these results. Conclusions. Immunization with the quadrivalent vaccine was a cost-effective intervention in Argentina, and it was far below the threshold of one gross domestic product per capita (US$15 009) per QALY gained.